genu
alphaviru
contain
member
threaten
human
health
natur
pathogen
potenti
biolog
weapon
peptideconjug
phosphorodiamid
morpholino
oligom
ppmo
enter
cell
readili
inhibit
viral
replic
sequencespecif
steric
blockad
viral
rna
sindbi
viru
sinv
low
pathogen
human
regularli
util
model
alphaviru
ppmo
target
aug
translat
start
siteregion
sinv
genom
block
product
infecti
sinv
tissu
cultur
ppmo
design
correspond
region
venezuelan
equin
enceph
viru
veev
likewis
found
effect
vitro
sever
strain
veev
mice
treat
ppmo
veev
infect
complet
protect
lethal
outcom
mice
receiv
postinfect
ppmo
treatment
partial
protect
level
viru
tissu
sampl
correl
anim
surviv
uninfect
mice
suffer
appar
illeffect
ppmo
treatment
thu
ppmo
appear
promis
candid
therapeut
develop
alphavirus
genu
alphaviru
famili
togavirida
consist
virus
cycl
mosquito
vector
vertebr
host
sever
alphavirus
includ
venezuelan
equin
enceph
viru
veev
eastern
equin
enceph
viru
eeev
western
equin
enceph
viru
weev
onyongnyong
viru
chikungunya
viru
caus
sever
diseas
human
typic
includ
fever
neurolog
sequela
griffin
veev
import
human
pathogen
sever
recent
outbreak
consist
hundr
thousand
case
occur
mostli
latin
america
weaver
et
al
furthermor
caus
sever
diseas
human
produc
larg
quantiti
andor
potenti
transmit
aerosol
eeev
weev
veev
consid
bioterrorist
threat
hawley
eitzen
sidwel
smee
veterinari
vaccin
vari
qualiti
eeev
weev
veev
commerci
avail
ind
prepar
approv
human
use
avail
limit
militari
laboratori
personnel
therapeut
alphavirusinduc
diseas
exist
although
support
treatment
antiinflammatori
drug
may
benefici
recent
short
interf
rna
sirna
shown
effect
alphavirus
semliki
forest
viru
caplen
et
al
veev
obrien
cell
cultur
onyongnyong
viru
replic
natur
mosquito
vector
anophel
gambia
keen
et
al
alphavirus
singl
positivestrand
rna
genom
approxim
kilobas
code
two
polyprotein
process
four
nonstructur
protein
three
structur
protein
respect
open
read
frame
flank
untransl
region
utr
approxim
nucleotid
respect
nonstructur
protein
translat
fulllength
genom
rna
util
produc
fulllength
negativestrand
antigenom
rna
negativestrand
intermedi
use
templat
produc
fulllength
positivestrand
use
nucleotid
intern
promot
kb
subgenom
rna
ident
sequenc
termin
third
genom
rna
structur
protein
translat
subgenom
rna
genom
subgenom
rna
cap
polyadenyl
sindbi
viru
sinv
extens
use
model
alphaviru
low
pathogen
human
easi
propag
varieti
cell
line
molecular
biolog
consid
repres
genu
antisens
oligom
variou
structur
type
use
interfer
gene
express
sever
human
viral
pathogen
schubert
kurreck
phosphorothio
oligonucleotid
design
target
mrna
cytomegaloviru
cmv
intend
treat
cmvinduc
retin
approv
drug
de
clercq
howev
antisens
therapeut
technolog
continu
hamper
limit
oligom
stabil
deliveri
rna
target
within
relev
cell
kurreck
phosphorodiamid
morpholino
oligom
pmo
class
oligonucleotidelik
antisens
agent
possess
four
base
dna
contain
differ
backbon
deoxyribos
ring
phosphodiest
linkag
dna
replac
morpholin
ring
phosphorodiamid
linkag
pmo
pmo
nonion
stabl
cellular
extract
human
serum
nelson
et
al
youngblood
et
al
typic
synthes
length
subunit
pmo
mechan
antisens
action
via
stericblock
complementari
rna
sequenc
stein
et
al
thu
differ
antisens
agent
base
dna
chemistri
induc
rnase
hmediat
cleavag
rna
strand
rnadna
duplex
rnaisirna
involv
doublestrand
agent
recogn
target
mrna
induc
degrad
cellular
protein
masiero
et
al
pmo
coval
conjug
cellpenetr
peptid
cpp
deliv
effici
cell
dea
et
al
moulton
et
al
yuan
et
al
zhang
et
al
cpp
watersolubl
shown
gener
potent
inhibit
sever
rna
virus
includ
dengu
viru
holden
et
al
kinney
et
al
west
nile
viru
dea
et
al
sar
coronaviru
neuman
et
al
equin
arteriviru
van
den
born
et
al
influenza
viru
ge
et
al
cell
cultur
coxsackieviru
yuan
et
al
ebola
viru
enterlein
et
al
murin
coronaviru
burrer
et
al
west
nile
viru
dea
et
al
cell
cultur
mous
model
two
differ
cppconjug
pmo
ppmo
one
contain
oligoarginin
one
contain
acid
util
ppmo
moulton
et
al
abe
et
al
recent
report
document
ppmo
highli
stabl
human
serum
least
hour
h
moder
stabl
h
youngblood
et
al
present
studi
first
evalu
six
sinvspecif
ppmo
design
base
pair
sequenc
four
termin
region
fulllength
genom
antigenom
aug
translat
startsit
region
polyprotein
code
sequenc
nonstructur
protein
subgenom
promot
region
negativestrand
antigenom
found
two
ppmo
one
target
sequenc
target
first
function
aug
translat
start
site
region
genom
effect
block
viral
product
subsequ
ppmo
design
target
two
correspond
region
veev
sinv
ppmo
veevspecif
ppmo
found
inhibit
replic
sever
veev
strain
cell
cultur
efficaci
murin
model
vee
consider
ppmo
sequenc
design
studi
includ
current
understand
function
variou
alphaviru
genet
region
ppmo
mechan
action
positivestrand
virus
util
capdepend
translat
access
transact
protein
termin
region
genom
critic
alphaviru
cap
reaction
process
translat
preiniti
vasiljeva
et
al
also
shown
mutat
studi
certain
sequenc
secondari
structur
requir
terminalregion
alphaviru
genom
must
present
effici
viral
replic
occur
frolov
hardi
rice
gorchakov
et
al
niester
strauss
tsiang
weiss
schlesing
termin
region
antigenom
likewis
shown
play
integr
role
positivestrand
synthesi
frolov
hardi
rice
perhap
presenc
stemloop
structur
correspond
invers
present
end
genom
specif
sequenc
requir
nucleotid
conserv
sequenc
element
immedi
preced
polya
tail
necessari
effici
minusstrand
synthesi
frolov
hardi
rice
anoth
studi
report
high
antivir
activ
ppmo
target
termin
region
equin
arteriviru
genom
moder
activ
ppmo
target
either
terminu
genom
terminu
antigenom
van
den
born
et
al
although
end
antigenom
includ
target
group
also
report
high
efficaci
ppmo
target
genom
termin
region
posit
strand
virus
includ
dengu
kinney
et
al
west
nile
viru
dea
et
al
porcin
reproduct
respiratori
syndrom
viru
zhang
et
al
murin
coronaviru
burrer
et
al
report
document
import
sequenc
structur
termin
region
alphaviru
genom
along
success
terminitarget
ppmo
led
us
design
ppmo
four
termini
sinv
genom
rna
fig
alphaviru
subgenom
sg
rna
encod
structur
protein
synthes
intern
initi
genomelength
negativestrand
rna
minim
sequenc
essenti
promot
activ
extend
nucleotid
relat
start
codon
sg
positivestrand
correspond
genom
positivestrand
sequenc
nucleotid
sinv
levi
schlesing
huang
therefor
target
corepromot
region
antigenom
effort
interfer
synthesi
plusstrand
sg
rna
genom
aug
codon
requir
translat
initi
nonstructur
protein
alphavirus
lemm
et
al
region
flank
translat
start
site
favor
target
site
pmo
mediat
silenc
viral
enterlein
et
al
neuman
et
al
van
den
born
et
al
cellular
heasman
naseviciu
ekker
mrna
obviou
ppmo
target
select
three
six
site
initi
chose
target
ppmo
region
highli
conserv
sequenc
either
alphaviru
speci
strain
within
speci
cse
terminu
genom
ii
sg
corepromot
region
iii
termin
region
lemm
et
al
impact
cell
viabil
evalu
mtt
assay
bhk
cell
follow
hour
incub
ppmo
sinv
sinv
aug
sinv
sgp
scr
rang
fig
cell
viabil
read
ppmo
concentr
test
rel
vehicletr
cell
greater
similar
cytotox
evalu
carri
ppmo
veev
scr
fig
viabil
assay
perform
quadrupl
multipl
time
point
h
concentr
use
fluorescencebas
assay
major
time
point
minim
differ
cell
viabil
comparison
untreat
ppmo
control
match
time
point
either
veev
ppmo
given
treatmenttim
point
reduct
viabil
exceed
major
ppmo
incub
statist
signific
decreas
viabil
detect
two
wayanova
bonferroni
pairwis
comparison
untreat
control
ppmo
match
concentr
time
point
except
veev
scr
h
time
point
reduct
viabil
assess
ppmo
could
success
inhibit
alphaviru
replic
well
confirm
util
recombin
full
length
sinbi
viru
express
luciferas
luc
report
protein
sinluc
tool
monitor
antisinv
compound
evalu
sinvtarget
ppmo
tabl
system
sinluc
viru
harvest
follow
electropor
bhk
cell
vitro
transcrib
sinluc
rna
prior
infect
sinluc
viru
bhk
cell
treat
sinv
concentr
rang
shown
noncytotox
shown
cell
viabil
experi
shown
fig
quantit
comparison
statist
analysi
perform
evalu
luc
level
group
ppmo
untreat
control
concentr
via
two
way
anova
well
pairwis
comparison
luc
level
sinv
ppmo
treatment
untreat
ppmo
concentr
correspond
scr
treatment
bonferroni
posttest
doserespons
inhibit
sinv
replic
repres
luc
read
observ
sinv
ppmo
right
panel
sinv
aug
ppmo
left
panel
sinv
aug
ppmo
reduct
rang
rel
scr
statist
signific
pvalu
sinv
reduct
dose
test
rang
signific
pvalu
contrast
level
inhibit
produc
sinv
similar
concentr
level
significantli
differ
scr
ppmo
pvalu
howev
reduct
appear
dose
depend
sgp
signific
differ
detect
major
concentr
test
except
howev
group
ppmo
untreat
control
luc
valu
gener
higher
rel
scr
statist
differ
scr
pvalu
thu
signific
doserespons
inhibit
observ
sinv
sinv
aug
ppmo
assess
abil
ppmo
inhibit
product
infecti
alphaviru
cell
cultur
bhk
cell
infect
wild
type
sinv
fig
panel
iii
perform
condit
similar
use
sinluc
viru
experi
shown
fig
sinvinfect
bhk
cell
incub
sinv
sinv
aug
sinv
sgp
sinv
ppmo
viru
product
level
determin
plaqu
assay
supernat
obtain
hpi
fig
statist
signific
reduct
titer
result
sinv
sinv
aug
ppmo
treatment
dunnett
test
ppmo
vs
mock
treatment
p
reduct
measur
sinv
sinv
aug
respect
level
inhibit
higher
p
respect
contrast
sinv
sgp
sinv
ppmo
affect
sinv
level
significantli
p
assess
viru
specif
effect
two
sinvspecif
pppmo
inhibit
viral
product
prior
experi
vero
cell
infect
moi
control
virus
vsv
veev
incub
sinv
aug
sinv
ppmo
concentr
control
vero
cell
infect
left
untreat
ppmo
vsv
titer
variabl
earlier
time
point
h
maximum
differ
titer
untreat
control
log
pfuml
sinv
aug
later
time
point
h
vsv
titer
similar
ppmo
maximum
differ
log
pfuml
titer
consist
h
maximum
differ
log
pfuml
h
maximum
differ
log
pfuml
obviou
trend
nonspecif
inhibit
ppmo
evid
effect
ppmo
viral
translat
assess
follow
sinv
sinv
aug
sinv
sgp
sinv
ppmo
treatment
sinvinfect
cell
cultur
quantif
level
viral
capsid
c
envelop
protein
slabel
bhk
cell
lysat
obtain
hpi
resolv
sdspage
indic
sinv
sinv
aug
ppmo
strongli
inhibit
viral
translat
capsid
protein
express
infect
untreat
cell
fig
contrast
incub
sinv
sgp
sinv
ppmo
produc
littl
inhibit
viral
translat
capsid
express
respect
rel
infect
mocktreat
cell
result
consist
sinv
sinv
aug
ppmomedi
inhibit
recombin
sinluc
fig
wildtyp
sinv
fig
vitro
transcrib
sinv
rna
use
program
rabbit
reticulocyt
lysat
fig
presenc
differ
ratio
molar
excess
sinv
fig
panel
human
rhinoviru
type
specif
ppmo
fig
panel
ii
none
specif
ppmo
inhibit
sinvdriven
translat
result
ident
observ
two
hrvtarget
ppmo
r
rijnbrand
manuscript
prepar
contrast
sinv
sinv
sgp
ppmo
inhibit
viral
translat
sinv
aug
show
strong
inhibit
viral
translat
sinv
aug
even
inhibit
molar
ratio
sinv
inhibit
translat
less
effici
ppmo
test
detect
protein
express
still
evid
presenc
molar
excess
base
observ
antisinv
effect
sinv
sinv
aug
ppmo
sinv
experi
ppmo
design
target
correspond
region
veev
synthes
fig
sinv
ppmo
synthes
peptid
compon
ppmo
two
veevspecif
antisens
scr
control
sequenc
prepar
morerec
develop
select
conjug
peptid
veev
experi
report
transport
ppmo
cell
equal
greater
abil
provid
peptid
abe
et
al
yet
stabl
youngblood
et
al
less
affect
serum
dea
et
al
less
cytotox
abe
et
al
vero
cell
infect
variou
strain
veev
control
vsv
prior
addit
veev
veev
aug
scr
ppmo
fig
left
panel
hpi
right
panel
supernat
harvest
analysi
viral
titer
via
plaqu
assay
time
point
viral
titer
veev
veev
augtreat
cultur
limit
detect
log
pfuml
veev
strain
contrast
vsv
control
viral
product
rel
unaffect
ppmo
treatment
vsv
level
rang
log
ml
log
pfuml
hpi
respect
rel
viru
product
differ
veev
strain
similar
time
point
howev
titer
hr
log
higher
experi
indic
veev
ppmo
effect
reduc
viru
product
hpi
multipl
strain
veev
despit
moder
level
nonspecif
activ
doserespons
experi
subsequ
perform
moi
incub
time
includ
addit
sampl
time
point
concentr
use
veev
conjug
fluoresc
label
amca
fig
control
scr
lower
dose
signific
reduct
viral
titer
detect
ppmo
treat
cell
comparison
scr
howev
ppmo
treatment
result
modest
reduct
dose
mark
reduct
dose
reduct
viru
product
pattern
observ
scrtreat
cell
compar
untreat
veevinfect
cell
concentr
time
point
test
assess
robust
natur
observ
qualit
differ
inhibit
veev
ppmo
addit
analysi
effect
veev
perform
fig
vero
cell
infect
veev
control
vsv
one
h
h
prior
addit
veev
veev
aug
scr
ppmo
supernat
collect
h
determin
level
viru
product
via
plaqu
assay
perform
eight
replic
statist
signific
differ
titer
level
detect
veev
ppmo
veev
aug
pairwis
comparison
either
scr
untreat
ppmo
control
bonferroni
p
veev
reduct
detect
h
respect
wherea
modest
reduct
detect
veev
aug
time
point
fig
panel
ii
h
small
statist
signific
titer
increas
detect
scr
treatment
comparison
untreat
ppmo
howev
signific
differ
h
p
treatment
combin
veev
veev
aug
evalu
two
concentr
mm
ppmo
shown
fig
vero
cell
infect
veev
control
vsv
one
h
h
prior
addit
combin
veev
supernat
collect
h
vsv
h
determin
level
viru
product
treatment
combin
veev
ppmo
percent
inhibit
rel
veev
infect
untreat
vero
cell
ppmo
shown
tabl
fig
bottom
similar
time
point
concentr
ppmo
contrast
vsv
overal
lower
percent
inhibit
result
treatment
combin
ppmo
inhibit
h
respect
ppmo
inhibit
respect
h
ppmo
substanti
differ
seen
h
inhibit
inhibit
anim
model
veev
use
infect
nih
swiss
mice
highli
virul
strain
welldescrib
paessler
et
al
paessler
et
al
mice
develop
enceph
paralysi
typic
succumb
diseas
day
postinfect
prior
experi
intranas
deliveri
vaccin
veev
mice
ni
et
al
suggest
us
novel
administr
rout
ppmo
use
combin
intranas
subcutan
deliveri
would
potenti
effect
neuroinvas
virus
veev
studi
report
use
mgkg
deliv
via
intraperiton
ip
wnv
dea
et
al
via
intraven
iv
rout
coxsackieviru
viru
yuan
et
al
nontox
provid
antivir
effect
evalu
antivir
efficaci
combin
veev
veev
aug
ppmo
treatment
measur
surviv
viral
titer
brain
peripher
organ
fig
mice
receiv
treatment
ppmo
prior
pre
follow
post
infect
pfu
virul
veev
death
occur
group
uninfect
mice
receiv
veevspecif
ppmo
infect
surviv
indic
dose
regimen
welltoler
veevinfect
group
survivor
group
receiv
preand
postinfect
treatment
scr
ppmo
contrast
group
receiv
preand
postinfect
treatment
veev
veev
aug
ppmo
surviv
group
receiv
postinfect
treatment
veevspecif
ppmo
surviv
statist
signific
differ
among
surviv
curv
logrank
p
statist
comparison
surviv
group
receiv
ppmo
treatment
infect
untreat
veevinfect
control
show
statist
signific
differ
fisher
exact
group
receiv
ppmo
treatment
infect
comparison
untreat
veevinfect
control
group
fisher
exact
evalu
veev
titer
three
earli
postinfect
time
point
dpi
brain
peripher
organ
four
randomli
select
mice
treat
ppmo
diluent
mock
treatment
ii
veev
ppmo
infect
iii
veev
ppmo
infect
fig
time
point
test
veev
undetect
blood
brain
peripher
tissu
liver
lung
spleen
mice
receiv
veev
ppmo
preand
postinfect
prepost
treatment
mice
receiv
postinfect
post
ppmo
treatment
reduct
veev
titer
vari
depend
upon
tissu
examin
blood
veev
titer
veev
treat
group
similar
mocktreat
mice
day
pi
log
lower
mock
treat
day
fig
panel
brain
veev
group
treat
follow
infect
show
higher
titer
day
lower
titer
day
compar
mocktreat
group
fig
panel
ii
notabl
dpi
veev
titer
veev
ppmo
reduc
pfug
tissu
level
near
limit
detect
assay
pfug
compar
mocktreat
mice
averag
liver
titer
mice
receiv
veev
ppmo
follow
infect
log
higher
dpi
log
less
dpi
fig
panel
iii
spleen
titer
group
receiv
veev
treatment
follow
infect
similar
mocktreat
mice
dpi
somewhat
lower
mock
dpi
consider
lower
undetect
level
mock
dpi
fig
panel
iv
lung
titer
similarli
low
mice
treat
veev
mocktreat
mice
dpi
dpi
mocktreat
mice
averag
titer
log
ppmo
treatment
group
undetect
titer
fig
panel
v
veev
highli
lethal
alphaviru
consider
human
veterinari
health
import
effect
human
vaccin
therapeut
veev
present
avail
alphavirus
exhibit
robust
replic
cell
cultur
anim
provid
excel
system
investig
antivir
efficaci
specif
ppmo
demonstr
potent
inhibit
sinv
varieti
veev
strain
cell
cultur
ppmo
target
region
genom
rna
importantli
abl
prevent
veevinduc
lethal
enceph
mous
model
studi
use
alphaviru
low
pathogen
human
sindbi
viru
guid
design
ppmo
highli
pathogen
veev
strategi
success
ppmo
design
target
correspond
sequenceregion
veev
highli
effect
vitro
vivo
veev
furthermor
result
luciferaseexpress
sinv
show
sinvspecif
ppmo
strong
inhibitor
viral
replic
fig
obtain
result
consist
result
use
wild
type
sinv
fig
valid
util
sinluc
drug
screen
reagent
six
ppmo
design
sinv
two
target
region
genom
rna
effect
inhibit
viral
replic
antivir
efficaci
ppmo
target
variou
locat
end
genom
positivestrand
rna
virus
observ
nidovirus
neuman
et
al
van
den
born
et
al
zhang
et
al
flavivirus
dea
et
al
kinney
et
al
picornavirus
vagnozzi
et
al
yuan
et
al
remain
undetermin
four
six
sinv
ppmo
studi
rel
ineffect
futur
studi
may
evalu
region
alphaviru
sequenc
prospect
ppmo
target
includ
terminaland
augregion
subgenom
rna
result
cell
cultur
fig
cellfre
translat
assay
fig
indic
activ
ppmo
identifi
studi
directli
interfer
viral
translat
lack
activ
sever
ppmo
incident
provid
confirm
specif
inhibitori
action
effect
ppmo
addit
experi
reveal
nonspecif
toxic
associ
ppmo
chemistri
would
reflect
overal
lower
luciferas
fig
plaqu
fig
viral
protein
product
fig
comparison
untreat
scrcontrol
evid
lack
toxic
compound
provid
cell
viabil
assay
ppmo
use
fig
data
shown
rel
low
inhibitori
activ
veevspecif
ppmo
vsv
fig
control
scr
ppmo
employ
throughout
studi
uncompromis
health
ppmotreat
uninfect
mice
fig
veev
aug
ppmo
highli
effect
multipl
strain
veev
cell
cultur
fig
surpris
consid
high
perfect
sequenc
conserv
ppmo
target
site
among
veev
strain
test
similar
sequenc
conserv
present
veev
strain
avail
genbank
data
shown
indic
two
ppmo
may
repres
use
antivir
treatment
enzoot
well
epidem
strain
veev
studi
design
target
correspond
conserv
sequenc
two
major
group
encephalit
alphavirus
eeev
weev
current
progress
complet
protect
provid
otherwiseleth
veevinduc
diseas
murin
model
antisens
ppmo
administ
infect
howev
postinfect
ppmo
treatment
confer
partial
protect
indic
ppmo
may
use
even
strictli
therapeut
set
tissu
titer
data
fig
reflect
surviv
profil
fig
mous
efficaci
experi
clearli
implic
reduct
viru
product
mechan
efficaci
antisens
ppmo
novel
ppmo
administr
scheme
employ
studi
subcutan
combin
intranas
deserv
explor
may
modif
rel
proport
dose
ppmo
deliv
two
inocul
rout
could
finetun
enhanc
efficaci
notabl
two
mode
administr
employ
prefer
intraven
inject
prospect
human
treatment
also
interest
explor
ppmo
efficaci
veev
strain
mous
model
veev
anim
model
pmo
synthes
avi
biopharma
inc
corval
method
previous
describ
sinvspecif
pmo
coval
conjug
end
argininerich
peptid
nh
r
f
cconh
abbrevi
veevspecif
pmo
nh
rxr
xbconh
x
acid
b
beta
alanin
abbrevi
conjug
purif
analysi
ppmo
perform
procedur
previous
describ
abe
et
al
moulton
et
al
addit
version
veev
scr
prepar
fluor
amca
acet
acid
sigmaaldrich
st
loui
mo
conjug
end
method
similar
describ
previous
carboxyfluorescein
conjug
pmo
moulton
et
al
design
specif
ppmo
ppmo
base
length
design
target
complementari
base
pair
region
sinv
veev
identifi
import
viral
rna
synthesi
translat
ppmo
sequenc
name
design
specifi
tabl
schemat
represent
target
locat
provid
figur
addit
pmo
random
sequenc
gc
content
name
scr
conjug
either
peptid
use
control
nonsequencespecif
activ
two
respect
ppmo
chemistri
preclud
unintent
hybrid
event
antisens
neg
control
ppmo
sequenc
screen
via
blast
http
wwwncbinlmnihgovblast
primat
murin
mrna
sequenc
addit
neg
control
screen
publish
alphaviru
sequenc
ppmo
target
human
rhinoviru
type
use
addit
control
sinv
vitro
translat
experi
prior
use
lyophil
ppmo
suspend
filtersteril
distil
water
concentr
mm
store
follow
veev
strain
use
roehrig
bolin
wang
et
al
berg
bank
tigertt
kinney
et
al
ricohess
et
al
oberst
parker
smith
scherer
dickerman
ordonez
alphaviru
stock
gener
growth
cell
cultur
viral
titer
stock
obtain
via
plaqu
assay
describ
previous
paessler
et
al
sindbi
viru
sinv
obtain
electropor
bhk
cell
rna
deriv
rice
et
al
clone
contain
infecti
copi
sinluc
gift
ilya
frolov
utmb
vesicular
stomat
viru
vsv
obtain
scott
weaver
babi
hamster
kidney
cell
line
bhk
american
type
cultur
collect
manassa
va
vero
cell
maintain
co
dulbecco
modifi
eagl
medium
dmem
hyclon
logan
ut
fetal
bovin
serum
antibiot
sinvspecif
ppmo
spectrophotometr
measur
reduct
mtt
bromid
formazan
perform
accord
manufactur
protocol
sigma
st
loui
mo
mosmann
bhk
cell
confluenc
incub
indic
ppmo
rang
hour
product
formazan
rel
mocktreat
cell
use
assess
ppmo
toxic
veevspecif
veev
veev
aug
control
scr
ppmo
viabil
assay
measur
convers
resazurin
resorufin
perform
use
reagent
promega
madison
wi
briefli
vero
cell
incub
ppmo
concentr
rang
one
hour
incub
media
remov
cell
incub
variou
time
period
h
treatment
perform
quadrupl
well
design
time
point
celltiterblu
ad
well
plate
incub
accord
manufactur
recommend
read
biotek
fluoresc
plate
reader
ex
em
nm
vitro
transcript
psinluc
electropor
rna
bhk
cell
perform
gener
viral
stock
infect
describ
previous
liljestrom
garoff
bhk
cell
infect
sinv
sinluc
multipl
infect
moi
treat
hour
post
infect
hpi
indic
ppmo
cell
incub
h
viru
product
determin
via
plaqu
assay
viru
product
via
quantit
luciferas
assay
promega
madison
wi
vitro
translat
reaction
perform
use
rabbit
reticulocyt
lysat
promega
describ
supplier
lysat
program
nanogram
lysat
resolv
sdspage
analyz
phosphor
imag
statist
analysi
averag
luciferas
level
obtain
triplic
measur
perform
use
twoway
analysi
varianc
anova
pairwis
comparison
sinv
ppmo
scr
use
bonferroni
posttest
use
graphpad
prism
graphpad
softwar
san
diego
california
usa
statist
analysi
level
viru
product
log
transform
obtain
quadrupl
triplic
valu
perform
use
oneway
anova
dunnett
multipl
comparison
test
pairwis
comparison
ppmo
treat
group
mocktreat
control
graphpad
prism
evalu
potenti
nonspecif
effect
sinv
ppmo
experi
perform
use
vero
cell
infect
vsv
veev
moi
treat
sinv
sinv
aug
scr
ppmo
hour
postinfect
hr
cell
supernat
harvest
hpi
determin
viral
titer
via
plaqu
assay
parallel
supernat
also
collect
untreat
infect
vero
cell
ppmo
viral
titrat
bhk
cell
infect
sinv
moi
treat
ppmo
hpi
smethionin
ad
cell
hpi
cell
harvest
h
later
cell
lysat
prepar
deterg
lysi
analyz
sdspage
follow
densitometri
storm
gel
imag
system
viral
protein
identifi
kda
c
kda
use
c
label
molecular
weight
marker
amersham
life
scienc
arlington
height
il
publish
previous
paessler
et
al
vero
cell
infect
moi
indic
strain
veev
neg
control
vsv
incub
h
h
indic
figur
legend
prior
addit
indic
veev
ppmo
aug
veev
scr
viru
contain
media
remov
indic
ppmo
ad
concentr
supernat
harvest
hpi
analysi
viral
titer
via
plaqu
assay
paessler
et
al
statist
analysi
viru
tier
log
transform
obtain
eight
replic
valu
indic
figur
legend
perform
use
oneway
anova
bonferroni
multipl
comparison
test
pairwis
comparison
group
combin
ppmo
treatment
perform
describ
briefli
vero
cell
infect
moi
indic
strain
veev
control
vsv
incub
h
prior
addit
ppmo
combin
veev
aug
veev
control
untreat
vero
cell
incub
parallel
plaqu
assay
supernat
obtain
h
latter
vsv
perform
nineweekold
nih
swiss
mice
purchas
harlan
spragu
dawley
inc
indianapoli
allow
acclimat
least
week
studi
approv
utmb
institut
anim
care
use
committe
work
veev
perform
biosafeti
accord
utmb
health
safeti
approv
guidelin
mice
allow
food
water
ad
libitum
throughout
studi
mice
treat
veevspecif
ppmo
combin
aug
equal
amount
random
control
ppmo
scr
serumfre
dmem
dose
per
mous
via
rout
via
sc
rout
time
point
pre
dose
hr
hr
indic
pre
andor
postinfect
dose
daili
day
indic
post
day
indic
group
infect
pfu
virul
veev
via
rout
control
group
consist
follow
veevspecif
ppmo
treat
veev
infect
mice
veev
infect
untreat
mice
mice
per
group
monitor
daili
death
period
follow
infect
day
postinfect
dpi
four
anim
per
group
euthan
harvest
blood
brain
peripher
organ
liver
spleen
lung
infecti
viru
level
tissu
determin
via
plaqu
assay
describ
previous
paessler
et
al
statist
analysi
surviv
group
indic
period
perform
use
logrank
test
signific
level
prism
san
diego
ca
pairwis
comparison
surviv
treat
untreat
mocktreat
group
fisher
exact
test
perform
signific
level
prism
schemat
represent
alphaviru
genom
shown
ppmo
design
target
termin
untransl
regulatori
region
utr
alphaviru
genom
antigenom
rna
label
ad
well
aug
translat
start
site
region
genom
label
e
subgenom
promot
region
antigenom
label
f
rna
sindbi
viru
sinv
venezuelan
equin
enceph
viru
veev
specif
ppmo
name
design
sequenc
shown
tabl
bhk
cell
incub
indic
sinvspecif
ppmo
sinv
sinv
aug
sinv
sgp
see
tabl
neg
control
scr
ppmo
random
nucleotid
sequenc
hour
reduct
cell
viabil
measur
mtt
assay
describ
materi
method
express
rel
mocktreat
cell
b
veev
ppmo
vero
cell
incub
veev
ppmo
see
tabl
neg
control
scr
ppmo
random
nucleotid
sequenc
rang
ppmo
concentr
differ
time
point
h
bhk
cell
infect
sinluc
multipl
infect
moi
follow
treatment
indic
concentr
sinv
aug
sinv
sgp
scr
ppmo
left
sinv
genom
termini
target
ppmo
right
h
luciferas
luc
level
measur
triplic
describ
materi
method
averag
standard
deviat
shown
statist
analysi
luciferas
level
sinv
ppmo
vs
scr
treatment
twoway
anova
pairwis
comparison
via
bonferroni
posttest
perform
result
describ
text
b
doserespons
inhibit
wild
type
sinv
panel
iii
effect
sinv
ppmo
sinv
product
bhk
cell
infect
sinv
moi
treat
hpi
indic
ppmo
panel
ii
respect
hpi
viru
level
supernat
sampl
determin
plaqu
assay
supernat
analyz
quadrupl
triplic
result
one
repres
experi
two
perform
shown
statist
analysi
perform
use
oneway
anova
dunnett
multipl
comparison
test
pairwis
comparison
ppmo
treat
group
rel
mock
control
statist
signific
differ
dunnett
test
indic
asterisk
pvalu
percent
reduct
shown
left
panel
iii
effect
sinv
ppmo
two
control
virus
vsv
vero
cell
infect
vsv
veev
moi
treat
hpi
indic
ppmo
h
viru
product
level
determin
plaqu
assay
viral
titrat
untreat
infect
vero
cell
ppmo
also
perform
result
singl
experi
shown
c
inhibit
viral
protein
express
sinvspecif
ppmo
bhk
cell
treat
indic
ppmo
start
h
infect
sinv
moi
hpi
cell
incub
smethionin
one
hour
cell
lysat
analyz
sdspage
molecular
weight
marker
shown
viral
capsid
c
envelop
protein
appar
molecular
mass
indic
arrow
percentag
c
express
rel
mocktreat
control
determin
densitometri
shown
numer
lane
inhibit
viral
translat
sinvspecif
ppmo
vitro
transcrib
sinv
rna
translat
rabbit
reticulocyt
lysat
presenc
molar
excess
indic
ppmo
describ
materi
method
sampl
separ
sdspage
visual
phosphor
imag
vero
cell
infect
moi
indic
strain
veev
neg
control
vesicular
stomat
viru
vsv
h
prior
addit
indic
ppmo
left
hpi
right
supernat
harvest
analysi
viral
titer
via
plaqu
assay
veev
serotyp
indic
parenthes
epizoot
epizoot
deriv
strain
enzoot
strain
horizont
line
depict
limit
detect
asterisk
indic
viru
detect
sampl
group
result
singl
experi
shown
b
ppmo
doserespons
inhibit
veev
vero
cell
infect
moi
veev
strain
h
prior
addit
indic
amcaconjug
ppmo
dose
rang
variou
time
point
postinfect
indic
graph
supernat
harvest
analysi
viral
titer
via
plaqu
assay
result
singl
experi
shown
c
effect
veev
ppmo
veev
control
viru
vsv
eight
replic
vero
cell
infect
moi
veev
strain
control
vsv
h
prior
addit
indic
ppmo
supernat
harvest
hpi
analysi
viral
titer
via
plaqu
assay
perform
eight
replic
time
point
veev
vsv
statist
analysi
perform
log
transform
viral
titer
valu
compar
treatment
use
oneway
analysi
varianc
graphpad
prism
pairwis
comparison
log
titer
valu
treatment
group
perform
use
bonferroni
posttest
bar
asterisk
indic
statist
signific
differ
bonferroni
pvalu
averag
percent
chang
calcul
log
titer
veev
ppmoaverag
nineweekold
nih
swiss
mice
treat
veevspecif
combin
veev
aug
veev
control
scr
dose
via
intranas
rout
via
subcutan
sc
rout
time
point
pre
dose
hr
hr
indic
pre
andor
postinfect
dose
daili
day
indic
post
treatment
group
indic
figur
legend
follow
aug
pre
post
veev
veevspecif
ppmo
time
point
prior
pre
follow
post
infect
graph
symbol
ppmoveev
treatment
veevinfect
mice
graph
symbol
scr
pre
post
veev
scr
treatment
preand
postinfect
time
point
graph
